Opportunities to Optimize Cancer Policies Panel Discussion

First International Summit on Interventional Pharmacoeconomics

Varsha Gandhi, PhD, on Ibrutinib

David A. Hyman, MD, JD, on Inclusive Shared Savings

Cost of Care

Health-Care Policy

The ASCO Post Staff

Blase N. Polite, MD, MPP, on Optimizing Cancer Policies in the United States

Blase N. Polite, MD, MPP, of the University of Chicago Medical Center, discusses his belief that, in the next few years, we can bend the cancer drug cost curve and tame health-care costs if physicians, pharmaceutical companies, payers, and government come together and agree on the value of treatments that improve survival and quality of life.

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Peter Clark, MA, MD, FRCP: A Payer Perspective

Nov

Today In Oncology

Opportunities to Optimize Cancer Policies Panel Discussion

Related Videos

Varsha Gandhi, PhD, on Ibrutinib

David A. Hyman, MD, JD, on Inclusive Shared Savings

Blase N. Polite, MD, MPP, on Optimizing Cancer Policies in the United States

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Peter Clark, MA, MD, FRCP: A Payer Perspective

Study Finds Gaps Exist in Quality of Cancer Care for Incarcerated People

Impact of Concomitant Noncancer Medications on Outcomes in Breast Cancer

NCCN Guidelines to Be Integrated Into OpenEvidence Medical AI Platform

Adding an Investigational Monoclonal Antibody to Ibrutinib May Allow Patients With CLL to Discontinue Daily Treatment

FDA Approves Daratumumab and Hyaluronidase-fihj for High-Risk Smoldering Multiple Myeloma